PTC Therapeutics - PTCT Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $56.30
Forecasted Upside: 11.09 %
Number of Analysts: 10
Breakdown:
1 Sell Ratings
4 Hold Ratings
5 Buy Ratings
0 Strong Buy Ratings

^$50.68 As of 10/3/2022 01:00 AM ET

▲ +0.48 (0.96%)

1 month | 3 months | 12 months

Get New PTC Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for PTCT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PTCT

^$56.30

▲ +11.09% Upside Potential

This price target is based on 10 analysts offering 12 month price targets for PTC Therapeutics in the last 3 months. The average price target is $56.30, with a high forecast of $76.00 and a low forecast of $38.00. The average price target represents a 11.09% upside from the last price of $50.68.

Current Consensus is Hold

The current consensus among 10 polled investment analysts is to hold stock in PTC Therapeutics. This rating has held steady since September 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
6 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

4/11/2021

0 strong buy ratings
7 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

7/10/2021

0 strong buy ratings
5 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

10/8/2021

0 strong buy ratings
4 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

1/6/2022

0 strong buy ratings
5 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

4/6/2022

0 strong buy ratings
3 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

7/5/2022

0 strong buy ratings
4 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

9/3/2022

0 strong buy ratings
5 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

10/3/2022

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
9/12/2022	Jefferies Financial Group	Initiated Coverage	Buy	$62.00	Low
9/9/2022	Morgan Stanley	Initiated Coverage	Equal Weight	$54.00	Low
9/1/2022	Citigroup	Initiated Coverage	Buy	$70.00	Low
8/11/2022	Raymond James	Boost Target	Outperform	$55.00 ➝ $60.00	Low
8/9/2022	Credit Suisse Group	Boost Target		$55.00	Low
7/22/2022	Credit Suisse Group	Boost Target		$52.00	Low
6/23/2022	Royal Bank of Canada	Boost Target	Sector Perform	$42.00 ➝ $46.00	Low
4/1/2022	Cantor Fitzgerald	Reiterated Rating	Overweight	$64.00 ➝ $63.00	N/A
2/23/2022	JPMorgan Chase & Co.	Boost Target	Overweight	$70.00 ➝ $76.00	High
2/23/2022	Barclays	Lower Target	Equal Weight	$40.00 ➝ $39.00	High
10/29/2021	Raymond James	Lower Target	Outperform	$70.00 ➝ $55.00	High
10/29/2021	Royal Bank of Canada	Lower Target	Sector Perform	$45.00 ➝ $42.00	Medium
10/29/2021	Credit Suisse Group	Lower Target	Neutral	$50.00 ➝ $48.00	High
10/18/2021	Bank of America	Downgrade	Neutral ➝ Underperform	$38.00	High
8/31/2021	UBS Group	Lower Target	Neutral	$55.00 ➝ $45.00	High
7/30/2021	Credit Suisse Group	Lower Target	Neutral	$54.00 ➝ $50.00	Low
6/3/2021	William Blair	Reiterated Rating	Buy		High
5/17/2021	Truist Financial	Lower Target	Buy	$75.00 ➝ $65.00	Low
4/26/2021	Credit Suisse Group	Initiated Coverage	Neutral	$54.00	High
3/29/2021	Royal Bank of Canada	Upgrade	Underperform ➝ Sector Perform	$47.00	Medium
2/26/2021	Cantor Fitzgerald	Lower Target	Overweight	$81.00 ➝ $75.00	High
2/12/2021	Bank of America	Downgrade	Buy ➝ Neutral		Low
1/5/2021	Smith Barney Citigroup	Upgrade	Neutral ➝ Buy		N/A
12/16/2020	Raymond James	Boost Target	Outperform	$63.00 ➝ $70.00	Medium
11/30/2020	Royal Bank of Canada	Downgrade	Sector Perform ➝ Underperform	$45.00	High
10/30/2020	Smith Barney Citigroup	Downgrade	Buy ➝ Neutral		Medium
10/30/2020	Cantor Fitzgerald	Lower Target	Overweight	$75.00 ➝ $67.00	High
10/28/2020	UBS Group	Initiated Coverage	Neutral	$55.00	Medium
10/7/2020	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$71.00	High
9/23/2020	Raymond James	Reiterated Rating	Buy		Medium
8/24/2020	Raymond James	Initiated Coverage	Outperform	$63.00	High
8/11/2020	Cantor Fitzgerald	Lower Target	Overweight	$85.00 ➝ $75.00	Low
8/10/2020	Bank of America	Lower Target	Buy	$60.00 ➝ $58.00	Medium
8/10/2020	Credit Suisse Group	Lower Target	Neutral	$53.00 ➝ $52.00	Low
7/20/2020	Cowen	Reiterated Rating	Hold	$50.00	High
7/20/2020	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$53.00	High
7/20/2020	SunTrust Banks	Boost Target	Buy	$75.00 ➝ $86.00	High
5/1/2020	SunTrust Banks	Lower Target	Buy	$78.00 ➝ $75.00	Medium
4/28/2020	William Blair	Reiterated Rating	Buy		Low
4/9/2020	Citigroup	Upgrade	Neutral ➝ Buy	$71.00 ➝ $67.00	High
4/8/2020	Cantor Fitzgerald	Lower Target	Overweight	$86.00 ➝ $85.00	Medium
4/8/2020	Royal Bank of Canada	Reiterated Rating	Hold	$45.00	High
3/4/2020	Barclays	Reiterated Rating	Hold	$51.00	High
3/3/2020	Cantor Fitzgerald	Reiterated Rating	Positive ➝ Overweight	$81.00 ➝ $86.00	High
3/2/2020	Cowen	Reiterated Rating	Hold		High
2/20/2020	Citigroup	Downgrade	Buy ➝ Neutral	$55.00 ➝ $71.00	High
2/20/2020	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$63.00 ➝ $60.00	High
2/6/2020	SunTrust Banks	Reiterated Rating	Buy	$78.00	Medium
2/6/2020	Cowen	Reiterated Rating	Hold		High
1/23/2020	Cantor Fitzgerald	Boost Target	Overweight	$60.00 ➝ $81.00	Low
1/15/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$60.00	Medium
12/5/2019	Royal Bank of Canada	Reiterated Rating	Outperform	$58.00	Medium
11/26/2019	William Blair	Reiterated Rating	Buy		Low
11/12/2019	SunTrust Banks	Initiated Coverage	Buy	$78.00	Low
10/31/2019	Credit Suisse Group	Reiterated Rating	Buy	$54.00	Low
10/30/2019	Cowen	Reiterated Rating	Hold		High
9/26/2019	Citigroup	Set Target	Buy	$62.00	High
9/24/2019	Royal Bank of Canada	Reiterated Rating	Buy		High
8/12/2019	Barclays	Reiterated Rating	Hold	$43.00	Low
5/13/2019	Bank of America	Upgrade	Neutral ➝ Buy	$43.00 ➝ $49.00	Low
5/8/2019	Cowen	Reiterated Rating	Hold		High
5/3/2019	Citigroup	Set Target	Buy	$59.00	Low
5/2/2019	Cowen	Reiterated Rating	Hold		High
4/11/2019	Sanford C. Bernstein	Initiated Coverage	Outperform	$48.00	Low
2/28/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$61.00	High
1/29/2019	Credit Suisse Group	Set Target	Buy	$51.00	High
1/7/2019	William Blair	Reiterated Rating	Buy		High
1/7/2019	Credit Suisse Group	Reiterated Rating	Buy	$55.00	High
1/7/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$61.00	High
11/12/2018	Cantor Fitzgerald	Lower Target	Overweight ➝ Overweight	$66.00 ➝ $61.00	High
11/6/2018	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$51.00 ➝ $46.00	High
11/6/2018	Barclays	Lower Target	Equal Weight ➝ Equal Weight	$43.00 ➝ $40.00	High
11/6/2018	William Blair	Reiterated Rating	Buy		High
11/5/2018	Credit Suisse Group	Set Target	Buy	$55.00	High
10/3/2018	Bank of America	Upgrade	Underperform ➝ Neutral		High
10/3/2018	Credit Suisse Group	Set Target	Buy	$55.00	Medium
10/3/2018	William Blair	Reiterated Rating	Buy		High
10/1/2018	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$66.00	Medium
9/28/2018	JPMorgan Chase & Co.	Boost Target	Positive ➝ Neutral	$51.00	Low
9/5/2018	Credit Suisse Group	Boost Target	Outperform ➝ Outperform	$49.00 ➝ $53.00	Low
8/8/2018	Barclays	Boost Target	Equal Weight ➝ Equal Weight	$40.00 ➝ $43.00	High
7/31/2018	Bank of America	Boost Target	Underperform ➝ Underperform	$27.00 ➝ $31.00	High
7/24/2018	Citigroup	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $50.00	Low
7/19/2018	Credit Suisse Group	Initiated Coverage	Outperform	$49.00	High
6/20/2018	Barclays	Upgrade	Underweight ➝ Equal Weight		High
6/18/2018	William Blair	Upgrade	Market Perform ➝ Outperform		High
6/18/2018	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$11.00	High
5/10/2018	William Blair	Reiterated Rating	Hold		High
4/3/2018	Barclays	Downgrade	Equal Weight ➝ Underweight	$24.00 ➝ $26.00	High
3/7/2018	Barclays	Reiterated Rating	Equal Weight ➝ Equal Weight	$18.00 ➝ $24.00	High
3/7/2018	William Blair	Reiterated Rating	Hold		High
2/21/2018	Citigroup	Boost Target	Buy ➝ Buy	$24.00 ➝ $35.00	High
1/30/2018	Credit Suisse Group	Reiterated Rating	Buy	$28.00	Medium
1/29/2018	Royal Bank of Canada	Initiated Coverage	Sector Perform ➝ Sector Perform		High
1/23/2018	Barclays	Reiterated Rating	Hold		Low
11/24/2017	JPMorgan Chase & Co.	Boost Target	Underweight ➝ Neutral	$15.00	N/A
11/16/2017	JPMorgan Chase & Co.	Upgrade	Underweight ➝ Neutral	$15.00	N/A
10/26/2017	Bank of America	Downgrade	Neutral ➝ Underperform		N/A
10/25/2017	Cowen	Reiterated Rating	Hold		N/A
10/25/2017	Royal Bank of Canada	Set Target	Hold	$15.00	N/A
10/9/2017	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight	$23.00 ➝ $15.00	N/A

(Data available from 10/4/2017 forward)

News Sentiment Rating

0.31 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

1 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/7/2022

1 very positive mentions
1 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

4/6/2022

1 very positive mentions
8 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

5/6/2022

5 very positive mentions
9 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

6/5/2022

4 very positive mentions
4 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

7/5/2022

3 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

8/4/2022

2 very positive mentions
3 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

9/3/2022

2 very positive mentions
6 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

10/3/2022

Current Sentiment

Recent Stories by Sentiment

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Today's Range

Now: $50.68

$49.40

$51.14

50 Day Range

MA: $50.62

$43.25

$53.85

52 Week Range

Now: $50.68

$25.01

$55.58

Volume

568,593 shs

Average Volume

601,583 shs

Market Capitalization

$3.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56

Frequently Asked Questions

What sell-side analysts currently cover shares of PTC Therapeutics?: The following sell-side analysts have issued research reports on PTC Therapeutics in the last twelve months: Bank of America Co., Barclays PLC, Cantor Fitzgerald, Citigroup Inc., Credit Suisse Group AG, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Raymond James, Royal Bank of Canada, and StockNews.com.
View the latest analyst ratings for PTCT.
What is the current price target for PTC Therapeutics?: 10 Wall Street analysts have set twelve-month price targets for PTC Therapeutics in the last year. Their average twelve-month price target is $56.30, suggesting a possible upside of 11.1%. JPMorgan Chase & Co. has the highest price target set, predicting PTCT will reach $76.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $38.00 for PTC Therapeutics in the next year.
View the latest price targets for PTCT.
What is the current consensus analyst rating for PTC Therapeutics?: PTC Therapeutics currently has 1 sell rating, 4 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PTCT, but not buy more shares or sell existing shares.
View the latest ratings for PTCT.
What other companies compete with PTC Therapeutics?: Other companies that are similar to PTC Therapeutics include ChemoCentryx, Zai Lab, Arrowhead Pharmaceuticals, Alkermes and Turning Point Therapeutics. Learn More about companies similar to PTC Therapeutics.
How do I contact PTC Therapeutics' investor relations team?: PTC Therapeutics' physical mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company's listed phone number is (908) 222-7000 and its investor relations email address is [email protected] The official website for PTC Therapeutics is www.ptcbio.com. Learn More about contacing PTC Therapeutics investor relations.

PTC Therapeutics - PTCT Stock Price Target and Predictions

Analyst Price Target for PTCT

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.31 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of PTC Therapeutics?

What is the current price target for PTC Therapeutics?

What is the current consensus analyst rating for PTC Therapeutics?

What other companies compete with PTC Therapeutics?

How do I contact PTC Therapeutics' investor relations team?